Genzyme Rival Gets FDA Nod

Xconomy Boston — 

Protalix BioTherapeutics, an Israel-based biotech company, said today it has received FDA approval for a treatment protocol of its experimental drug for Gaucher’s disease, which will allow patients to get expanded access to the drug during a shortage of the leading therapy, Genzyme’s imiglucerase (Cerezyme). Shares of Protalix (AMEX: PLX) climbed 10 percent in mid-day trading on the news.